Additionally, the pro-inflammatory pathway was shown to increase AKR1C1/2 levels in non-small cell lung cancer cells leading to cisplatin and doxorubicin resistance [58]. This evidence concerns the gene AKR1C1 and non-small cell lung carcinoma.